abstract |
Sphingosine-1 -phosphate analogs that are potent, and selective agonists at one or more SlP receptors, specifically the S1P1 receptor type are provided. The disclosed compounds include an optional phosphate moiety as well as compounds with hydrolysis-resistant phosphate surrogates such as phosphonates, alpha- substituted phosphonates, and phosphothionates. |